Amylin Pharmaceuticals Inc. (AMLN)

[SeriousMoney]

Amylin Pharmaceuticals Added to the NASDAQ-100 Index
PR, Monday January 9, 7:15 am ET

SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) announced that, effective today, it has been added to the NASDAQ-100 Index®, which is composed of the 100 largest non-financial stocks on The NASDAQ Stock Market® based on market capitalization and eligibility criteria.

"We are pleased to be included on the NASDAQ-100 Index and listed among the top companies in the world," said Ginger L. Graham, President and CEO of Amylin Pharmaceuticals, Inc. "It is particularly meaningful following our company's successful transition to a fully commercial organization in 2005 and the market adoption of our first-in-class diabetes products BYETTA® and SYMLIN®."

Amylin has a market capitalization of $4.4 billion.

About the NASDAQ-100 Index

The NASDAQ-100 Index, launched in January 1985, is one of the most widely followed benchmarks in the world. The NASDAQ-100 Index Tracking Stock represents ownership in the NASDAQ-100 Trust. The Trust holds a portfolio of equity securities that compose the NASDAQ-100 Index and aims to provide investment results that generally correspond with the performance of the Index.

NASDAQ® is the largest electronic screen-based equity securities market in the United States. With approximately 3,200 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. It is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin is located in San Diego, California with over 1000 employees nationwide. Further information on Amylin Pharmaceuticals and its pipeline in metabolism is available at http://www.amylin.com .

http://biz.yahoo.com/prnews/060109/nym120.html?.v=27